SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...

The FDA approval of crinecerfont (Crenessity; Neurocrine Biosciences) on December 13, 2024, marked a significant milestone in the management of classic congenital adrenal hyperplasia (CAH), ...

Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up ...

Crinetics Pharmaceuticals announced positive topline results from a Phase 2 study of atumelnant, a novel oral ACTH receptor antagonist, for treating congenital adrenal hyperplasia (CAH).

(Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral ...

Crinetics Pharma reports positive results from phase 2 trial of atumelnant in congenital adrenal hyperplasia: San Diego Monday, January 13, 2025, 16:30 Hrs [IST] Crinetics Pharmac ...

Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.

The U.S. Food and Drug Administration (FDA) has granted approval to crinecerfont, an innovative oral drug designed to treat classic congenital adrenal hyperplasia (CAH) in patients aged four years ...

Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) traded sharply lower after the company posted initial data from a Phase 2 ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

Pratishtha Sharma, representative of PGIMER, informed that over the next three years, nearly 30,000 antenatal care (ANC) women in Moga will be screened for HbA2 (hemoglobin) levels using ...